Jørg Mørland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jørg Mørland has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Asbjørg S. Christophersen
Norwegian Institute of Public Health, P. O. Box 4404, Nydalen, NO-0403 Oslo Norway
6 shared publications - Fernando Boix
Section of Forensic Research, Department of Forensic Sciences Oslo University Hospital Oslo Norway
4 shared publications - Gudrun Høiseth
Norwegian Center for Addiction Research (SERAF), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Forensic Sciences, Oslo University Hospital, Oslo, Norway; Center for psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
4 shared publications - Svetlana Skurtveit
Norwegian Centre for Addiction Research Institute of Clinical Medicine University of Oslo Oslo Norway
3 shared publications - Hallvard Gjerde
Department of Forensic Sciences, Oslo University Hospital
2 shared publications - Hassan Z. Khiabani
Divisjon for rettstoksikologi og rusmiddelforskning, Nasjonalt folkehelseinstitutt, Postboks 4404 Nydalen, 0403 Oslo
2 shared publications
Latest Publications
- Open Access
- 3 August 2024
- Published by Elsevier in Forensic Science International
- Vol. 363, 112180
The relationship between clinical impairment and blood drug concentration: Comparison between the most prevalent traffic relevant drug groups
- 3 August 2024
- Published by Elsevier in Forensic Science International
- Vol. 363, 112180
Open AccessThe relationship between clinical impairment and blood drug concentration: Comparison between the most prevalent traffic relevant drug groups
- Open Access
- 24 June 2024
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 144 (8)
Faste grenser for andre rusgivende stoff enn alkohol i veitrafikken
24.06.2024: Kronikk - Veitrafikklovens promillegrenser for alkohol er allment akseptert i befolkningen, men det er blitt stilt spørsmål ved legalgrensene for andre psykoaktive stoff.
- 24 June 2024
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 144 (8)
Open AccessFaste grenser for andre rusgivende stoff enn alkohol i veitrafikken
24.06.2024: Kronikk - Veitrafikklovens promillegrenser for alkohol er allment akseptert i befolkningen, men det er blitt stilt spørsmål ved legalgrensene for andre psykoaktive stoff.
- Open Access
- 10 August 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 418-427
Heroin metabolism in human blood and its impact for the design of an immunotherapeutic approach against heroin effects
Immunotherapeutic interventions that block drug effects by binding drug molecules to specific antibodies in the bloodstream have shown promising effects in animal studies. For heroin, which effects are mainly mediated by the metabolites 6‐acetylmorphine (6‐AM; also known as 6‐monoacetylmorphine or 6‐MAM) and morphine, the optimal antibody specificity has been discussed. In rodents, 6‐AM specific antibodies have been recommended based on the rapid metabolism of heroin to 6‐AM in the bloodstream. Since the metabolic rate of heroin in blood is unsettled in humans, we examined heroin metabolism with state‐of–the‐art analytical methodology (UHPLC–MS/MS) in freshly drawn human whole blood incubated with a wide range of heroin concentrations (1–500 μM). The half‐life of heroin was highly concentration dependent, ranging from 1.2–1.7 min for concentrations at or above 25 μM, and gradually increasing to approximately 20 min for 1 μM heroin. At concentrations that can be attained in the bloodstream shortly after an i.v. injection, approximately 70% was transformed into 6‐AM within 3 min, similar to previous observations in vivo. Our results indicate that blood enzymes play a more important role for the rapid metabolism of heroin in humans than previously assumed. This points to 6‐AM as an important target for an efficient immunotherapeutic approach to block heroin effects in humans.
- 10 August 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 418-427
Open AccessHeroin metabolism in human blood and its impact for the design of an immunotherapeutic approach against heroin effects
Immunotherapeutic interventions that block drug effects by binding drug molecules to specific antibodies in the bloodstream have shown promising effects in animal studies. For heroin, which effects are mainly mediated by the metabolites 6‐acetylmorphine (6‐AM; also known as 6‐monoacetylmorphine or 6‐MAM) and morphine, the optimal antibody specificity has been discussed. In rodents, 6‐AM specific antibodies have been recommended based on the rapid metabolism of heroin to 6‐AM in the bloodstream. Since the metabolic rate of heroin in blood is unsettled in humans, we examined heroin metabolism with state‐of–the‐art analytical methodology (UHPLC–MS/MS) in freshly drawn human whole blood incubated with a wide range of heroin concentrations (1–500 μM). The half‐life of heroin was highly concentration dependent, ranging from 1.2–1.7 min for concentrations at or above 25 μM, and gradually increasing to approximately 20 min for 1 μM heroin. At concentrations that can be attained in the bloodstream shortly after an i.v. injection, approximately 70% was transformed into 6‐AM within 3 min, similar to previous observations in vivo. Our results indicate that blood enzymes play a more important role for the rapid metabolism of heroin in humans than previously assumed. This points to 6‐AM as an important target for an efficient immunotherapeutic approach to block heroin effects in humans.
- Open Access
- 13 February 2023
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 52 (4) , 1257-1267
Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20–79 years
Benefits of elevated high-density lipoprotein cholesterol (HDL-C) levels are challenged by reports demonstrating U-shaped relations between HDL-C levels and all-cause mortality; the association with cause-specific mortality is less studied. A total of 344 556 individuals (20–79 years, 52 % women) recruited from population-based health screening during 1985–2003 were followed until the end of 2018 for all-cause and cause-specific mortality by serum HDL-C level at inclusion of 99 mg/dl (< 0.78, 0.78–1.01, 1.04–1.27, 1.30–1.53, 1.55–1.79, 1.81–2.04, 2.07–2.31, 2.33–2.56, >2.56 mmol/L). Hazard ratios (HRs) were adjusted for sex, age, calendar period, smoking, total cholesterol, triglycerides, systolic blood pressure, physical activity, educational length, body mass index and ill health. During a mean follow-up of 22 years, 69 505 individuals died. There were U-shaped associations between HDL-C levels and all-cause, cancer and non-cardiovascular disease/non-cancer mortality (non-CVD/non-cancer), whereas for CVD there was increased risk of death only at lower levels. With HDL-C stratum 50–59 mg/dl (1.30–1.53 mmol/L) as reference, HRs [95% confidence intervals (CIs)] for levels >99 mg/dl (>2.56 mmol/L) were 1.32 (1.21–1.43), 1.05 (0.89–1.24), 1.26 (1.09–1.46) and 1.68 (1.48–1.90) for all–cause, CVD, cancer and non–CVD/non–cancer mortality, respectively. For HDL-C levels <30 mg/dl (0.78 mmol/L), the corresponding HRs (95% CIs) were 1.30 (1.24–1.36), 1.55 (1.44–1.67), 1.14 (1.05–1.23) and 1.19 (1.10–1.29). The mortality from alcoholic liver disease, cancers of mouth-oesophagus-liver, chronic liver diseases, chronic obstructive pulmonary disease, accidents and diabetes increased distinctly with increasing HDL-C above the reference level. HDL-C levels lower than the reference level were mainly associated with increased mortality of ischaemic heart disease (IHD), other CVDs, stomach cancer and diabetes. Higher HDL-C levels were associated with increased mortality risk of several diseases which also have been associated with heavy drinking, and lower HDL-C levels were associated with increased mortality from IHD, other CVDs, gastric cancer and diabetes.
- 13 February 2023
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 52 (4) , 1257-1267
Open AccessAssociations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20–79 years
Benefits of elevated high-density lipoprotein cholesterol (HDL-C) levels are challenged by reports demonstrating U-shaped relations between HDL-C levels and all-cause mortality; the association with cause-specific mortality is less studied. A total of 344 556 individuals (20–79 years, 52 % women) recruited from population-based health screening during 1985–2003 were followed until the end of 2018 for all-cause and cause-specific mortality by serum HDL-C level at inclusion of 99 mg/dl (< 0.78, 0.78–1.01, 1.04–1.27, 1.30–1.53, 1.55–1.79, 1.81–2.04, 2.07–2.31, 2.33–2.56, >2.56 mmol/L). Hazard ratios (HRs) were adjusted for sex, age, calendar period, smoking, total cholesterol, triglycerides, systolic blood pressure, physical activity, educational length, body mass index and ill health. During a mean follow-up of 22 years, 69 505 individuals died. There were U-shaped associations between HDL-C levels and all-cause, cancer and non-cardiovascular disease/non-cancer mortality (non-CVD/non-cancer), whereas for CVD there was increased risk of death only at lower levels. With HDL-C stratum 50–59 mg/dl (1.30–1.53 mmol/L) as reference, HRs [95% confidence intervals (CIs)] for levels >99 mg/dl (>2.56 mmol/L) were 1.32 (1.21–1.43), 1.05 (0.89–1.24), 1.26 (1.09–1.46) and 1.68 (1.48–1.90) for all–cause, CVD, cancer and non–CVD/non–cancer mortality, respectively. For HDL-C levels <30 mg/dl (0.78 mmol/L), the corresponding HRs (95% CIs) were 1.30 (1.24–1.36), 1.55 (1.44–1.67), 1.14 (1.05–1.23) and 1.19 (1.10–1.29). The mortality from alcoholic liver disease, cancers of mouth-oesophagus-liver, chronic liver diseases, chronic obstructive pulmonary disease, accidents and diabetes increased distinctly with increasing HDL-C above the reference level. HDL-C levels lower than the reference level were mainly associated with increased mortality of ischaemic heart disease (IHD), other CVDs, stomach cancer and diabetes. Higher HDL-C levels were associated with increased mortality risk of several diseases which also have been associated with heavy drinking, and lower HDL-C levels were associated with increased mortality from IHD, other CVDs, gastric cancer and diabetes.
- Open Access
- 19 February 2021
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 56 (6) , 718-725
Alcohol Consumption, HDL-Cholesterol and Incidence of Colon and Rectal Cancer: A Prospective Cohort Study Including 250,010 Participants
Alcohol consumption has been linked to colorectal cancer (CRC) and also to the high-density lipoprotein cholesterol level (HDL-C). HDL-C has been associated with the incidence of CRC. The aim of this study was to investigate the association between self-reported alcohol consumption, HDL-C and incidence of CRC, separately for the two sites. Altogether, 250,010 participants in Norwegian surveys have been followed-up for an average of 18 years with respect to a first-time outcome of colon or rectal cancer. During follow-up, 3023 and 1439 colon and rectal cancers were registered. For men, the HR per 1 drink per day was 1.05 with 95% confidence interval (0.98–1.12) for colon and 1.08 (1.02–1.15) for rectal cancer. The corresponding figures for women were 1.03 (0.97–1.10) and 1.05 (1.00–1.10). There was a positive association between alcohol consumption and HDL-C. HDL-C was inversely associated with colon cancer in men (0.74 (0.62–0.89) per 1 mmol/l) and positively associated with rectal cancer, although not statistically significant (1.15 (0.92–1.44). A robust regression that assigned weights to each observation and exclusion of weights ≤ 0.1 increased the HRs per 1 drink per day and decreased the HR per 1 mmol/l for colon cancer. The associations with rectal cancer remained unchanged. Our results support a positive association between alcohol consumption and colon and rectal cancer, most pronounced for rectal cancer. Considering the positive relation between alcohol consumption and HDL-C, the inverse association between HDL-C and colon cancer in men remains unsettled.
- 19 February 2021
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 56 (6) , 718-725
Open AccessAlcohol Consumption, HDL-Cholesterol and Incidence of Colon and Rectal Cancer: A Prospective Cohort Study Including 250,010 Participants
Alcohol consumption has been linked to colorectal cancer (CRC) and also to the high-density lipoprotein cholesterol level (HDL-C). HDL-C has been associated with the incidence of CRC. The aim of this study was to investigate the association between self-reported alcohol consumption, HDL-C and incidence of CRC, separately for the two sites. Altogether, 250,010 participants in Norwegian surveys have been followed-up for an average of 18 years with respect to a first-time outcome of colon or rectal cancer. During follow-up, 3023 and 1439 colon and rectal cancers were registered. For men, the HR per 1 drink per day was 1.05 with 95% confidence interval (0.98–1.12) for colon and 1.08 (1.02–1.15) for rectal cancer. The corresponding figures for women were 1.03 (0.97–1.10) and 1.05 (1.00–1.10). There was a positive association between alcohol consumption and HDL-C. HDL-C was inversely associated with colon cancer in men (0.74 (0.62–0.89) per 1 mmol/l) and positively associated with rectal cancer, although not statistically significant (1.15 (0.92–1.44). A robust regression that assigned weights to each observation and exclusion of weights ≤ 0.1 increased the HRs per 1 drink per day and decreased the HR per 1 mmol/l for colon cancer. The associations with rectal cancer remained unchanged. Our results support a positive association between alcohol consumption and colon and rectal cancer, most pronounced for rectal cancer. Considering the positive relation between alcohol consumption and HDL-C, the inverse association between HDL-C and colon cancer in men remains unsettled.
- Open Access
- 1 October 2020
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 44 (8) , 861-863
The Relationship Between Ingested Dose of Ethanol and Amount of Ethyl Glucuronide Formed in Blood
A positive non-linear relation between the dose of ethanol ingested and the area under the curve (AUC) for ethyl glucuronide (EtG) in urine is previously observed. The relation between both doses and AUC of ethanol and the AUC for EtG in blood is not previously published, and this study aimed to investigate this relationship. After an overnight fast, 10 healthy volunteers ingested 0.5-g ethanol per kilo body weight (low dose) in one occasion and 1.0-g ethanol per kilo body weight (high dose) in the next occasion. Results showed that there was a significant higher median ratio between blood AUC for EtG and dose of ethanol in the high-dose (8.99; range 7.37-10.94) group compared to the low-dose (5.02; range 4.25-6.15) group (P = 0.005). The median ratio between the AUC for EtG and AUC for ethanol was actually significantly higher in the low-dose (1.77; range 1.51-2.24) group compared to the high-dose (1.67; range 1.30-2.02) group (P = 0.005), although values are quite similar. This study therefore showed that the ratio between the AUC for EtG in blood and dose of ethanol is higher after intake of 1.0 g/kg than 0.5 g/kg. This pattern is however not seen when AUC for EtG is compared to AUC for ethanol. Results therefore support that the percentage of ethanol converted to EtG is not increasing when the doses increase. An explanation for the positive non-linear relation previously observed between the dose of ethanol ingested and amount of EtG formed may be a relative higher first-pass metabolism of ethanol at lower doses.
- 1 October 2020
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 44 (8) , 861-863
Open AccessThe Relationship Between Ingested Dose of Ethanol and Amount of Ethyl Glucuronide Formed in Blood
A positive non-linear relation between the dose of ethanol ingested and the area under the curve (AUC) for ethyl glucuronide (EtG) in urine is previously observed. The relation between both doses and AUC of ethanol and the AUC for EtG in blood is not previously published, and this study aimed to investigate this relationship. After an overnight fast, 10 healthy volunteers ingested 0.5-g ethanol per kilo body weight (low dose) in one occasion and 1.0-g ethanol per kilo body weight (high dose) in the next occasion. Results showed that there was a significant higher median ratio between blood AUC for EtG and dose of ethanol in the high-dose (8.99; range 7.37-10.94) group compared to the low-dose (5.02; range 4.25-6.15) group (P = 0.005). The median ratio between the AUC for EtG and AUC for ethanol was actually significantly higher in the low-dose (1.77; range 1.51-2.24) group compared to the high-dose (1.67; range 1.30-2.02) group (P = 0.005), although values are quite similar. This study therefore showed that the ratio between the AUC for EtG in blood and dose of ethanol is higher after intake of 1.0 g/kg than 0.5 g/kg. This pattern is however not seen when AUC for EtG is compared to AUC for ethanol. Results therefore support that the percentage of ethanol converted to EtG is not increasing when the doses increase. An explanation for the positive non-linear relation previously observed between the dose of ethanol ingested and amount of EtG formed may be a relative higher first-pass metabolism of ethanol at lower doses.
- Open Access
- 22 January 2018
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 138 (2)
J. Mørland & J.G. Bramness svarer
22.01.2018: Kommentar - Advokat Dagfinn Hessen Paust kommer med et nokså krast angrep på vår kronikk om hvor lenge effektene av cannabis varer.
- 22 January 2018
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 138 (2)
Open AccessJ. Mørland & J.G. Bramness svarer
22.01.2018: Kommentar - Advokat Dagfinn Hessen Paust kommer med et nokså krast angrep på vår kronikk om hvor lenge effektene av cannabis varer.
- 1 September 2017
- Published by Elsevier in Forensic Science International
- Vol. 278, 177-183
Zopiclone concentrations in oral fluid and blood after, administration of therapeutic doses of zopiclone
- 1 September 2017
- Published by Elsevier in Forensic Science International
- Vol. 278, 177-183
Zopiclone concentrations in oral fluid and blood after, administration of therapeutic doses of zopiclone
- 1 November 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 156, e23
Heroin metabolism in blood and not in brain is critical to its acute effects
- 1 November 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 156, e23
Heroin metabolism in blood and not in brain is critical to its acute effects